EXCHANGE-2:探究附加血浆置换作为脓毒性休克辅助策略的疗效——一项随机、前瞻性、多中心、开放标签、对照、平行组试验的研究方案
EXCHANGE-2是一项随机、前瞻性、多中心、开放标签、对照、平行组干预试验,旨在验证早期治疗性血浆置换对早期难治性脓毒性休克的辅助疗效。纳入难治性(去甲肾上腺素≥0.4 μg/kg/min持续≥30分钟,或去甲肾上腺素0.3 μg/kg/min联合血管加压素)且早期(休克发生<24小时)脓毒性休克患者,干预组在随机化后6小时内进行标准治疗性血浆置换(供体新鲜冰冻血浆,1.2倍个体血浆容量),对照组为标准治疗。主要终点为28天死亡率,把握度分析显示每组需137例(共274例)以证明15%的获益。
要点
- 纳入难治性(去甲肾上腺素≥0.4 μg/kg/min≥30分钟或0.3 μg/kg/min联合血管加压素)且早期(休克发生<24小时)脓毒性休克患者。
- 干预为随机化后6小时内进行标准治疗性血浆置换,使用供体新鲜冰冻血浆1.2倍个体血浆容量,对照为标准治疗。
- 主要终点为28天死亡率,每组137例(共274例)以证明15%的获益。
核心结论
- 研究者假设早期治疗性血浆置换可通过清除损伤性介质减轻适应不良的宿主反应,从而限制器官功能障碍并改善脓毒性休克患者的生存,但尚无足够把握度的随机临床试验研究硬终点。
研究设计与样本
- 随机、前瞻性、多中心、开放标签、对照、平行组干预试验,由研究者发起,德国研究基金会(DFG,DA 1209/7-1)支持。
- 计划在德国、瑞士和奥地利的26个中心开展,持续时间33个月。
- 把握度分析显示每组137例(共274例)以证明15%的获益。
- 干预组在随机化后6小时内进行标准治疗性血浆置换(供体新鲜冰冻血浆,1.2倍个体血浆容量),对照组为标准治疗。
关键数值与推荐
- 纳入标准:难治性(去甲肾上腺素≥0.4 μg/kg/min持续≥30分钟,或去甲肾上腺素0.3 μg/kg/min联合血管加压素)且早期(休克发生<24小时)脓毒性休克。
- 主要终点:28天死亡率。
- 关键次要目标:比较随机化后前7天平均SOFA评分以及截至第28天的无器官支持天数。
- 安全性终点:前7天内评估出血、过敏反应、输血相关肺损伤、严重血小板减少症及其他严重不良事件的发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis is as a life-threatening organ dysfunction caused by a dysregulated host response to an infection. The mortality of sepsis and particular of septic shock is very high. Treatment mostly focuses on infection control but a specific intervention that targets the underlying pathological host response is lacking to the present time. The investigators hypothesize that early therapeutic plasma exchange (TPE) will dampen the maladaptive host response by removing injurious mediators thereby limiting organ dysfunction and improving survival in patients with septic shock. Although small prospective studies demonstrated rapid hemodynamic stabilization under TPE, no adequately powered randomized clinical trial has investigated hard outcomes. METHODS: This is a randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of TPE in patients with early septic shock. Patients with a refractory (defined as norepinephrine (NE) ≥ 0.4 μg/kg/min ≥ 30 min OR NE 0.3 μg/kg/min + vasopressin) and early (shock onset < 24 h) septic shock will be included. The intervention is a standard TPE with donor fresh frozen plasma (1.2 × individual plasma volume) performed within 6 h after randomization and will be compared to a standard of care (SOC) control arm. The primary endpoint is 28 days mortality for which the power analysis revealed a group size of 137 / arm (n = 274) to demonstrate a benefit of 15%. The key secondary objective will be to compare the extent of organ failure indicated by mean SOFA over the first 7 days as well as organ support-free days until day 28 following randomization. Besides numerous biological secondary, safety endpoints such as incidence of bleeding, allergic reactions, transfusion associated lung injury, severe thrombocytopenia, and other severe adverse events will be assessed during the first 7 days. For exploratory scientific analyses, biomaterial will be acquired longitudinally and multiple predefined scientific subprojects are planned. This study is an investigator-initiated trial supported by the German Research Foundation (DFG, DA 1209/7-1), in which 26 different centers in Germany, Switzerland, and Austria will participate over a duration of 33 months. DISCUSSION: This trial has substantial clinical relevance as it evaluates a promising adjunctive treatment option in refractory septic shock patients suffering from an extraordinary high mortality. A positive trial result could change the current standard of care for this septic subgroup. The results of this study will be disseminated through presentations at international congresses, workshops, and peer-reviewed publications. TRIAL REGISTRATION: ClinicalTrials.gov NCT05726825 , Registered on 14 February 2023.
引用
- David S, Bode C, Stahl K, et al. EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock-a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial. Trials. 2023. PMID: 37061693. doi:10.1186/s13063-023-07300-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。